Larimar Therapeutics (LRMR) Retained Earnings (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Retained Earnings for 14 consecutive years, with $624.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 292.38% year-over-year to $624.5 million; the trailing twelve-month figure through Jun 2026 stood at $624.5 million (up 292.38% YoY), and the FY2025 full-year result was $512.8 million, up 290.51% from the prior year.
• Retained Earnings grew to $624.5 million in Q2 2026 per LRMR's latest filing, from $512.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $624.5 million in Q2 2026 and bottomed at -$372.3 million in Q3 2025.
• Historically, Retained Earnings has averaged -$119.8 million across 5 years, with a median of -$175.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings tumbled 61.13% in 2022, then soared 292.38% in 2026.
• Over 5 years, Retained Earnings stood at -$151.6 million in 2022, then dropped by 24.37% to -$188.6 million in 2023, then plunged by 42.75% to -$269.2 million in 2024, then jumped by 290.51% to $512.8 million in 2025, then climbed by 21.79% to $624.5 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $624.5 million, $512.8 million, and -$372.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.